Read by QxMD icon Read

Leukemia lymphoma pediatric oncology

Subramanyam Padma, Palaniswamy Shanmuga Sundaram, Anshu Tewari
(18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) is a well-established imaging modality in adult oncological practice. Its role in childhood malignancies needs to be discussed as paediatric malignancies differ from adults in tumor subtypes and they have different tumor biology and FDG uptake patterns. This is also compounded by smaller body mass, dosimetric restrictions, and physiological factors that can affect the FDG uptake. It calls for careful planning of the PET study, preparing the child, the parents, and expertise of nuclear physicians in reporting pediatric positron emission tomography/computed tomography (PET/CT) studies...
July 2016: Indian Journal of Medical and Paediatric Oncology
Jennifer Teichman, Angela Punnett, Sumit Gupta
There are currently no clinic-level quality of care metrics for outpatient pediatric oncology. We sought to develop a list of quality of care metrics for a leukemia-lymphoma (LL) clinic using a consensus process that can be adapted to other clinic settings. Medline-Ovid was searched for quality indicators relevant to pediatric oncology. A provisional list of 27 metrics spanning 7 categories was generated and circulated to a Consensus Group (CG) of LL clinic medical and nursing staff. A Delphi process comprising 2 rounds of ranking generated consensus on a final list of metrics...
July 27, 2016: Journal of Pediatric Hematology/oncology
Rebecca Citrin, Jessica B Foster, David T Teachey
INTRODUCTION: Proteasome inhibitors have garnered interest as novel chemotherapeutic agents based on their ability to inhibit the growth of cancer cells by altering the balance of intracellular proteins. Initial clinical trials of this drug class focused on bortezomib, a reversible inhibitor of the 20S proteasome, with promising results for the treatment of adult hematologic malignancies, including multiple myeloma and non-Hodgkin lymphoma. AREAS COVERED: This article will review the use of bortezomib and other proteasome inhibitors in both adult and pediatric populations, with a focus on their use in pediatrics...
September 2016: Expert Review of Hematology
Manuel Monsonís Cabedo, Susana Rives Solá, Antoni Noguera-Julian, Mireia Urrea Ayala, Ofelia Cruz Martinez, Amadeu Gené Giralt
INTRODUCTION: The routine use of a single aerobic bottle for blood culture in pediatric patients has become commonplace, as anaerobic bacteria are not frequently involved in clinically significant infections. The aim of this study was to assess the usefulness of routinely performing anaerobic blood cultures in pediatric oncology patients. METHODS: Prospective study was conducted on pediatric (<18 years) patients affected with febrile syndrome after receiving chemotherapy for hematological or solid malignancies...
May 21, 2016: Enfermedades Infecciosas y Microbiología Clínica
Simone Cesaro, Mara Cavaliere, Anna Pegoraro, Piergiorgio Gamba, Nicola Zadra, Gloria Tridello
We report our decennial experience with 1161 newly-placed long-term central venous catheters inserted in 919 hematology-oncology patients for a total of 413,901 CVC-days of observation. Most of the CVCs were partially-implanted, open-ended, Broviac-Hickman type of CVC (95 %). One thousand and twenty-four complications were recorded equal to 2.47 per 1000 CVC-days. The frequency of complications per CVC, the rate of episodes per 1000 CVC-days, and removal rate were malfunction/occlusion 42 %, 1.18/1000, and 2...
April 2016: Annals of Hematology
Matthias Klinger, Jonathan Benjamin, Roman Kischel, Sabine Stienen, Gerhard Zugmaier
Bispecific T-cell engager (BiTE(®)) antibody constructs represent a novel immunotherapy that bridges cytotoxic T cells to tumor cells, thereby inducing target cell-dependent polyclonal T-cell activation and proliferation, and leading to apoptosis of bound tumor cells. Anti-CD19 BiTE(®) blinatumomab has demonstrated clinical activity in Philadelphia chromosome (Ph)-negative relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL) eventually resulting in conditional approval by the U.S. Food and Drug Administration in 2014...
March 2016: Immunological Reviews
Matthew D Ramirez, Ann C Mertens, Natia Esiashvili, Lillian R Meacham, Karen Wasilewski-Masker
BACKGROUND: The Children's Oncology Group (COG) publishes consensus guidelines with screening recommendations for early identification of treatment-related morbidities among childhood cancer survivors. We sought to estimate the yield of recommended yearly urinalysis screening for genitourinary complications as per Version 3.0 of the COG Long-Term Follow-Up Guidelines and identify possible risk factors for abnormal screening in a survivor population. PROCEDURE: A database of pediatric cancer survivors evaluated between January 2008 and March 2012 at Children's Healthcare of Atlanta was queried for survivors at risk for genitourinary late effects...
May 2016: Pediatric Blood & Cancer
Barbara L Asselin, Meenakshi Devidas, Lu Chen, Vivian I Franco, Jeanette Pullen, Michael J Borowitz, Robert E Hutchison, Yaddanapudi Ravindranath, Saro H Armenian, Bruce M Camitta, Steven E Lipshultz
PURPOSE: To determine the oncologic efficacy, cardioprotective effectiveness, and safety of dexrazoxane added to chemotherapy that included a cumulative doxorubicin dose of 360 mg/m(2) to treat children and adolescents with newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic non-Hodgkin lymphoma (L-NHL). PATIENTS AND METHODS: Patients were treated on Pediatric Oncology Group Protocol POG 9404, which included random assignment to treatment with or without dexrazoxane given as a bolus infusion immediately before every dose of doxorubicin...
March 10, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Wei Liu, Shimin Hu, Marina Konopleva, Joseph D Khoury, Neda Kalhor, Guilin Tang, Carlos E Bueso-Ramos, Jeffrey L Jorgensen, Pei Lin, L Jeffrey Medeiros, Xinyan Lu
MYC and BCL2 translocations in B-cell lymphomas are defined as "double-hit" associated with poor prognosis in adult patients. Such double-hit events are extremely rare in B-cell precursor acute lymphoblastic leukemia (BCP-ALL), especially in pediatric patients or young adults. This study is to investigate the clinical manifestation of de novo MYCyBCL2 double-hit BCP-ALL in young patients. Two pediatric and one young adult patients were identified after a retrospective data review and all without previous history of lymphoma...
2015: Pediatric Hematology and Oncology
Katharine E Brock, Angela Steineck, Clare J Twist
BACKGROUND: Decisions about end-of-life care may be influenced by cultural and disease-specific features. We evaluated associations of demographic variables (race, ethnicity, language, religion, and diagnosis) with end-of-life characteristics (Phase I enrollment, do-not-resuscitate (DNR) orders, hospice utilization, location of death), and trends in palliative care services delivered to pediatric hematology, oncology, and stem cell transplant (SCT) patients. PROCEDURE: In this single-center retrospective cohort study, inclusion criteria were as follows: patients aged 0-35 who died between January 1, 2002 and March 1, 2014, and had been cared for in the pediatric hematology, oncology, and SCT divisions...
March 2016: Pediatric Blood & Cancer
Souichi Adachi
There are about 180 cases of childhood acute myeloid leukemia (AML) in Japan annually. For differential diagnosis and risk stratification of AML treatment, different diagnostic methods such as morphology, immunophenotyping, chimeric gene, chromosome and gene analysis are essential. According to the guidelines of JSPHO (Japanese Society of Pediatric Hematology/Oncology), different treatments for APL, ML-DS, and de novo AML have been carried out according to the JPLSG (Japan Pediatric Leukemia and Lymphoma Study Group) protocols...
October 2015: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
Simone Santana Viana, Leyla Manoella Maurício Rodrigues de Lima, Juliana Brito do Nascimento, Carlos André Ferreira Cardoso, Ana Carolina Dantas Rosário, Cristiano de Queiroz Mendonça, Osvaldo Alves de Menezes-Neto, Rosana Cipolotti
BACKGROUND: The treatment for ALL has evolved in recent decades and as a result survival rates are now close to 90% in many developed countries. However, this is not the case in developing countries where survival rates are often below 35%. More than 80% of children who are affected by ALL worldwide live in developing countries. The objective of this study was to evaluate the secular trend in mortality for children with ALL living in Sergipe, a state in northeastern Brazil, and to investigate any association with variables that relate to socioeconomic status...
October 2015: Leukemia Research
Véronique Minard-Colin, Laurence Brugières, Alfred Reiter, Mitchell S Cairo, Thomas G Gross, Wilhelm Woessmann, Birgit Burkhardt, John T Sandlund, Denise Williams, Marta Pillon, Keizo Horibe, Anne Auperin, Marie-Cécile Le Deley, Martin Zimmerman, Sherrie L Perkins, Martine Raphael, Laurence Lamant, Wolfram Klapper, Lara Mussolin, Hélène A Poirel, Elizabeth Macintyre, Christine Damm-Welk, Angelo Rosolen, Catherine Patte
Non-Hodgkin lymphoma is the fourth most common malignancy in children, has an even higher incidence in adolescents, and is primarily represented by only a few histologic subtypes. Dramatic progress has been achieved, with survival rates exceeding 80%, in large part because of a better understanding of the biology of the different subtypes and national and international collaborations. Most patients with Burkitt lymphoma and diffuse large B-cell lymphoma are cured with short intensive pulse chemotherapy containing cyclophosphamide, cytarabine, and high-dose methotrexate...
September 20, 2015: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Ching-Hon Pui, Jun J Yang, Stephen P Hunger, Rob Pieters, Martin Schrappe, Andrea Biondi, Ajay Vora, André Baruchel, Lewis B Silverman, Kjeld Schmiegelow, Gabriele Escherich, Keizo Horibe, Yves C M Benoit, Shai Izraeli, Allen Eng Juh Yeoh, Der-Cherng Liang, James R Downing, William E Evans, Mary V Relling, Charles G Mullighan
PURPOSE: To review the impact of collaborative studies on advances in the biology and treatment of acute lymphoblastic leukemia (ALL) in children and adolescents. METHODS: A review of English literature on childhood ALL focusing on collaborative studies was performed. The resulting article was reviewed and revised by the committee chairs of the major ALL study groups. RESULTS: With long-term survival rates for ALL approaching 90% and the advent of high-resolution genome-wide analyses, several international study groups or consortia were established to conduct collaborative research to further improve outcome...
September 20, 2015: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Daisuke Tomizawa
Treatment of infants with acute lymphoblastic leukemia (ALL), especially those with mixed lineage leukemia (MLL) rearrangement (MLL-r), which account for approximately 80% of cases, is still a major challenge for pediatric hematologists and oncologists worldwide. Continuing efforts by collaborative clinical study groups in Europe, North America, and Japan have rescued approximately half of the MLL-r ALL patients with intensive chemotherapy with or without allogeneic hematopoietic stem cell transplantation. Recent progress has clarified the unique mechanism of MLL-r ALL: the aberrant methylation and histone modifications via DOT1L and other related molecules by MLL fusion proteins lead to leukemogenetic gene expression, thus to overt leukemia...
October 2015: Pediatrics International: Official Journal of the Japan Pediatric Society
Sébastien Héritier, Karine Morand, Mary-France Courcoux, Guy Leverger
The paediatric haematology day hospital administers almost all types of chemotherapy used to treat acute lymphoblastic leukaemia. Blood transfusions, myelograms and lumbar punctures are also performed there. The prevention of pain and anxiety generated by the care is a priority.
July 2015: Soins. Pédiatrie, Puériculture
Michael J Borowitz, Brent L Wood, Meenakshi Devidas, Mignon L Loh, Elizabeth A Raetz, Wanda L Salzer, James B Nachman, Andrew J Carroll, Nyla A Heerema, Julie M Gastier-Foster, Cheryl L Willman, Yunfeng Dai, Naomi J Winick, Stephen P Hunger, William L Carroll, Eric Larsen
Minimal residual disease (MRD) is highly prognostic in pediatric B-precursor acute lymphoblastic leukemia (B-ALL). In Children's Oncology Group high-risk B-ALL study AALL0232, we investigated MRD in subjects randomized in a 2 × 2 factorial design to receive either high-dose methotrexate (HD-MTX) or Capizzi methotrexate (C-MTX) during interim maintenance (IM) or prednisone or dexamethasone during induction. Subjects with end-induction MRD ≥0.1% or those with morphologic slow early response were nonrandomly assigned to receive a second IM and delayed intensification phase...
August 20, 2015: Blood
Ryan C Johnson, Olga K Weinberg, Michael J Cascio, Gary V Dahl, Bryan A Mitton, Lewis B Silverman, Athena M Cherry, Daniel A Arber, Robert S Ohgami
OBJECTIVES: B-lymphoblastic leukemia (B-ALL) with intrachromosomal amplification of chromosome 21 (iAMP21) is a relatively uncommon manifestation of acute leukemia and limited predominantly to the pediatric population. Case-specific information regarding flow cytometric, morphologic, and laboratory findings of this subtype of leukemia is currently lacking. METHODS: We searched the databases of three large institutions for lymphoblastic leukemia with iAMP21 from 2005 through 2012 and analyzed the clinicopathologic features...
July 2015: American Journal of Clinical Pathology
Michael H Chan, Frederick Boop, Ibrahim Qaddoumi
PURPOSE: As the morbidity and mortality associated with communicable diseases continue to decrease in the developing world, the medical burden of childhood cancer continues to expand. Although international aid and relief groups such as the World Health Organization recognize the importance of childhood cancer, their main emphasis is on the more easily treated malignancies, such as leukemias and lymphomas, and not pediatric brain tumors, which are the second most common malignancy in children and the leading cause of cancer-related deaths in the pediatric population...
August 2015: Child's Nervous System: ChNS: Official Journal of the International Society for Pediatric Neurosurgery
Eric J Chow, Barbara L Asselin, Cindy L Schwartz, David R Doody, Wendy M Leisenring, Sanjeev Aggarwal, K Scott Baker, Smita Bhatia, Louis S Constine, David R Freyer, Steven E Lipshultz, Saro H Armenian
PURPOSE: Given concerns that dexrazoxane may reduce treatment efficacy, induce second cancers, and thus compromise overall survival among children, we examined long-term overall and cause-specific mortality and disease relapse rates from three randomized clinical trials. PATIENTS AND METHODS: Children's Oncology Group trials P9404 (T-cell acute lymphoblastic leukemia/lymphoma; n = 537), P9425 (intermediate/high-risk Hodgkin lymphoma; n = 216), and P9426 (low-risk Hodgkin lymphoma; n = 255) were conducted between 1996 and 2001...
August 20, 2015: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"